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with at least 1cm margin. In view of considerable variability 
between different authors, there is an obvious need for the 
international consensus guidelines. 
 
Poster: Clinical track: Lower GI (colon, rectum, anus)  
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Purpose or Objective: Aim of this clinical study was to 
evaluate resectability and pathological response after 
preoperative concurrent chemotherapy with 2 different drugs 
and radiation therapy (RT) intensified with concomitant 
boost. 
 
Material and Methods: A clinical trial based on two-stage 
Simon’s design was planned. The trial included a first phase 
with enrolment of 9 patients. If 0/9 patients had complete 
pathologic response (pCR) the study had to be closed. In case 
of ≥ 1/9 patients with pCR it was planned to enrol other 8 
patients. RT was performed with 3D-conformal technique. 
The dose to mesorectum and pelvic lymph nodes was 45 Gy 
(1.8 Gy/fraction). A concomitant boost was delivered to GTV 
+ 2 cm margin with a total dose of 55 Gy (2.2 Gy/fraction). 
The following concurrent chemotherapy was administered: 
Raltitrexed (3 mg/m2) and Oxaliplatin (130 mg/m²) on days 
1, 17, 35 of RT. Acute and late toxicities were evaluated 
according to CTC-AE v.3.0 criteria. 
 
Results: All 9 patients enrolled in the 1st phase underwent 
radical surgical resection, with 4/9 pCR. Then, 9 additional 
patients were enrolled for a total of 18 patients (F: 8, M: 10; 
median age 64.5, range: 45-80; clinical stage: 2 local 
recurrences, 16 cT4, 6 cN0, 4 cN1, 7 cN2, 1 cN3). Seventeen 
patients underwent surgical resection (7 anterior resections 
and 9 abdominal-perineal amputation) while 2 patients did 
not undergo surgery for early metastatic progression (1) or 
surgery refusal (1). R0 resection was achieved in all patients 
who underwent surgery. Overall, 5 patients had pCR and 2 
patients showed only microscopic residual disease (pT0-Tmic: 
7/17 = 41.2%). Acute grade ≥ 3 toxicity was: 1 leucopoenia -
neutropenia, 1 liver toxicity, 5 gastro-intestinal toxicities, 
with an overall incidence of 7/18 patients (38.9%). The 
actuarial analysis showed the following 2-year results: local 
control 100%, metastasis-free survival 93.7%, overall survival 
92.3%. 
 
Conclusion: The regimen used in this study allowed to 
achieve complete and near-complete response rate higher 
than 40%, despite the advanced stage of disease. However, 
severe acute toxicity was reported in more than 1/3 of 
patients. 
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Purpose or Objective: Aim of this analysis was to describe 
the results of a phase II study based on the use of VMAT in 
preoperative combined treatment of locally advanced rectal 
cancer. 
 
Material and Methods: A clinical trial based on two-stage 
Simon’s design was planned. The trial includes a 1st phase 
enrolment of 9 patients. If 0/9 patients had complete 
pathologic response (pCR) the study had to be closed. In the 
case of ≥ 1/9 patients with pCR it was scheduled to enrol 
other 8 patients. Radiation therapy was performed using 
VMAT-SIB technique. The dose to mesorectum and pelvic 
lymph nodes was 45 Gy (1.8 Gy/fraction). A concomitant 
boost was delivered on GTV + 2 cm margin with a total dose 
of 57.5 Gy (2.3 Gy/fraction). The following concomitant 
chemotherapy was administered: Capecitabine (825 mg/m² 
twice daily, 5 days/week) and Oxaliplatin (130 mg/m² on 
days 1, 17, 35). Acute and late toxicities were evaluated 
according to CTC-AE v. 3.0 criteria. 
 
Results: All 9 patients enrolled in the 1st phase underwent 
radical surgical resection, with 4/9 pCR. Then 9 additional 
patients were enrolled for a total of 18 patients (F: 7, M: 11; 
median age 62, range: 39-79); clinical stage: 4 local 
recurrences, 6 cT4, 5 cT3, 3 cT2, 2 cN0, 7 cN1, 9 cN2). 
Sixteen patients underwent surgical resection (9 anterior 
resection, 6 abdominal perineal amputations and 1 trans-anal 
resection) while 2 patients did not undergo surgery for early 
metastatic progression (1) or death from acute pulmonary 
oedema prior to surgery (1). R0 resection was achieved in all 
patients who underwent surgery. Overall, 4 patients had a 
pCR and 7 patients only a microscopic residual of disease 
(pT0-Tmic: 11/18 = 61.1%). Acute grade ≥ 3 toxicity was: 1 
leukopenia-neutropenia, 1 skin toxicity, 1 genitourinary 
toxicity and 5 gastrointestinal toxicities, with an overall 
incidence (considering the patient who died after radio 
chemotherapy) of 7/18 patients (38.9%). The actuarial 
analysis reported the following 2-year results: local control 
80%, metastasis-free survival 93.7%, overall survival 88.9%. 
 
Conclusion: The regimen used in this study showed excellent 
results in terms of pathologic responses (pT0-Tmic: 61.1%). 
However, despite the use of VMAT technique, more than 1/3 
of patients had severe acute toxicity. 
 
 
 
